Sernova Team Participates at Key US Life Sciences Event: 2014 BIO International Convention, San Diego

Sernova Corp. (TSX VENTURE:SVA), a clinical stage company developing disruptive
medical technologies for the long-term treatment of chronic diseases such as
diabetes and haemophilia announced today that it is participating at the US BIO
International Convention in San Diego, June 23-26th. 


"This is an excellent occasion for Sernova to present to international
institutions, pharma and potential collaborators to update attendees on our
progress and pipeline," remarked Dr. Philip Toleikis, President and CEO. 


The convention is an important annual business development forum which allows
high-level executives and influential decision makers attending BIO to liaise
with key players in the industry, form partnerships, and evaluate emerging
technologies. 


"Sernova's entire business development team is attending and has numerous
one-on-one meetings booked to discuss its proprietary platform - many important
collaborations mark their origins to BIO," remarked Kevin Egan, chair of
Sernova's Business Advisory Board.


About Sernova 

Sernova Corp. is a clinical stage regenerative medicine company developing
medical technologies for the treatment of chronic debilitating metabolic
diseases such as diabetes, blood disorders including haemophilia and other
diseases treated through replacement of proteins or hormones missing or in short
supply within the body. Sernova is developing the Cell Pouch(TM), an implantable
medical device for therapeutic cells (donor, xenogeneic or stem cells) which
then release proteins and/or hormones as required. The therapeutic cells are
protected from immune attack by Sernova's proprietary technologies.  


Forward-Looking Information 

This release may contain forward-looking statements. Forward-looking statements
are statements that are not historical facts and are generally, but not always,
identified by the words "expects", "plans", "anticipates", "believes",
"intends", "estimates", "projects", "potential" and similar expressions, or that
events or conditions "will", "would", "may", "could" or "should" occur. Although
Sernova believes the expectations expressed in such forward-looking statements
are based on reasonable assumptions, such statements are not guarantees of
future performance and actual results may differ materially from those in
forward-looking statements. Forward-looking statements are based on the beliefs,
estimates and opinions of Sernova's management on the date such statements were
made. Sernova expressly disclaims any intention or obligation to update or
revise any forward-looking statements whether as a result of new information,
future events or otherwise. 


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Sernova Corp.
Philip Toleikis, Ph.D.
President and CEO
[phone]
[e-mail] / [e-mail]
www.sernova.com


Ray Matthews & Associates
Ray Matthews
[phone]
www.raymatthews.ca